Basal cell carcinoma epidemiology in the UK: the elephant in the room

Levell, N. J.; Igali, Laszlo; Wright, Karen A.; Greenberg, David

doi:10.1111/ced.12016

Cited by 31 publications

(25 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eighty per cent of NMSCs are BCCs . The incidence of BCC is as high as the incidence of all other cancers combined, and its incidence continues to increase, also affecting ever‐younger populations . BCC is causing a remarkable burden via healthcare costs, treatment capacity and the morbidity of affected individuals …”

Section: Introductionmentioning

confidence: 99%

“…2 The incidence of BCC is as high as the incidence of all other cancers combined, and its incidence continues to increase, also affecting ever-younger populations. [3][4][5] BCC is causing a remarkable burden via healthcare costs, treatment capacity and the morbidity of affected individuals. 1,2,4 Histologically, BCCs can be classified by their morphological growth pattern into indolent (nodular and superficial) or aggressive (micronodular, morpheaform, infiltrative and metatypicali.e.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hyperspectral imaging system in the delineation of Ill‐defined basal cell carcinomas: a pilot study

Salmivuori

Neittaanmäki

Pölönen

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Hyperspectral imaging system in the delineation of Ill‐defined basal cell carcinomas: a pilot study

Salmivuori

Neittaanmäki

Pölönen

et al. 2018

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…Basal cell carcinoma (BCC) represents the most common (~80%) form of skin cancer worldwide in white people and its incidence is rising in many countries, although it is not systematically reported in tumor registries [1]. Metastatic spread is extremely rare, but the incidence of locally advanced BCC (laBCC) has been estimated around 8/100,000/year and is associated with substantial morbidity, since most tumors occur in functional areas [2, 3].…”

Section: Introductionmentioning

confidence: 99%

Basal cell carcinoma: 10-year experience with electrochemotherapy

et al. 2017

View full text Add to dashboard Cite

BackgroundElectrochemotherapy (ECT), by combining manageable cytotoxic agents with short electric pulses, represents an effective palliative skin-directed therapy. The accumulated evidence indicates that ECT stands out as a safe and well-tolerated alternative treatment for patients with multiple or large basal cell carcinoma (BCC), who are not suitable for conventional treatments. However, long-term data and shared indications are lacking.MethodsIn this observational study, we retrospectively analyzed 84 prospectively collected patients with multiple, recurrent or locally advanced BCC who were not candidate for standard therapies and received bleomycin-based ECT according to the European Standard Operative Procedures of ECT, from 2006 to 2016.ResultsDisease extent was local, locally advanced and metastatic in 40 (48%), 41 (49%) and 3 (3%), respectively. Forty-four (52%) individuals had multiple BCCs. Grade 3 skin toxicity after ECT was observed in 6% of cases. Clearance rate was 50% (95% CI 39–61%). Primary presentation (p = 0.004), tumor size <3 cm (p < 0.001), well-defined borders (p = 0.021), absence of tumor ulceration (p = 0.001), non-aggressive BCC histology (p = 0.046) and age ≤69 years were associated with higher complete response rate. In patients with local BCC, the clearance rate was 72.5 and 85% after one or two ECT cycles, respectively. In the laBCC group, 32 patients (78%) achieved an objective response. Five-year recurrence rate for local and laBCC was 20 and 38%, respectively (p ≤ 0.001).ConclusionsOne or two ECT cycles with bleomycin may be a valuable palliative treatment in well-selected patients with multiple BCCs and favorable tumor features. Validation of predictive factors will be imperative to match patients with optimal ECT treatment modalities. Management of laBCC with ECT warrants further investigation. Trial registration ISRCTN14633165 Registered 24 March 2017 (retrospectively registered)Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-017-1225-5) contains supplementary material, which is available to authorized users.

show abstract

“…Over the 13‐year study periods stated above, the population of ENW increased by approximately 10·4% at a steady rate . Our recorded data for the numbers of BCCs and SCCs (the dominant cancers in NMSC) from the study periods are very clear.…”

Section: East Norfolk and Waveney (Enw) Data On Cases Of Nonmelanoma mentioning

confidence: 72%

Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology

et al. 2016

Self Cite

View full text Add to dashboard Cite

Basal cell carcinoma epidemiology in the UK: the elephant in the room

Abstract: These data indicate that in the UK, BCC is nearly as common as all other cancers in all other body sites combined.

Cited by 31 publications

References 1 publication

Hyperspectral imaging system in the delineation of Ill‐defined basal cell carcinomas: a pilot study

Hyperspectral imaging system in the delineation of Ill‐defined basal cell carcinomas: a pilot study

Basal cell carcinoma: 10-year experience with electrochemotherapy

Predicted cases of U.K. skin squamous cell carcinoma and basal cell carcinoma in 2020 and 2025: horizon planning for National Health Service dermatology and dermatopathology

Contact Info

Product

Resources

About